Biovail

Source: www.marketwatch.com --- 15 days ago
NEW YORK (MarketWatch) -- Biovail Corp. said Thursday it was appointing Peggy Mulligan as chief financial officer, effective Sept. 3. Mulligan succeeds Adrian De Saldanha, who had been serving as Biovail's interim CFO. Mulligan was most recently a principal at Priiva Consulting Corp., a game theory consulting practice, it said. ...

Source: www.financialpost.com --- 24 days ago
Biovail Corp., whose shareholders recently approved an incumbent slate of directors ending an ugly proxy fight, reported a second-quarter loss on Wednesday, hurt by restructuring charges and legal and proxy contest costs. ...

Source: finance.sympatico.msn.ca --- 29 days ago
...

Source: finance.sympatico.msn.ca --- 24 days ago
...

Source: finance.sympatico.msn.ca --- 29 days ago
...

Source: www.financialpost.com --- 29 days ago
The shareholders of drugmaker Biovail Corp. approved its incumbent slate of directors during a vote on Friday. ...

Source: finance.sympatico.msn.ca --- 24 days ago
...

Source: finance.sympatico.msn.ca --- 24 days ago
...

Source: finance.sympatico.msn.ca --- 24 days ago
...

Source: www.marketwatch.com --- 24 days ago
Drug stocks inch higher while shares of Biovail Corp. lose ground after the drugmaker reports a second-quarter loss due in part to lower sales. ...

Source: www.cbc.ca --- 24 days ago
Canada's biggest publicly traded drug company lost money and saw its sales shrink in the second quarter as it absorbed the costs of a proxy fight, a management change and a losing legal battle. ...

Source: network.nationalpost.com --- 23 days ago
RBC Capital Markets analyst Doug Miehm offered qualified support for drug maker Biovail Corp.'s much talked about strategic shift into central nervous system drugs, praising management for doing "a good job" of explaining the new focus. However, in a note to clients Mr. Miehm went on to say he believes the company faces significant risk in implementation. Developing new treatments for central nervous system conditions is a highly competitive area, and many observers believe the risks are particularly great for a company like Biovail that is struggling with declining revenues. Biovail this week posted second quarter earnings of US37¢ a share,slightly ahead of Mr. Miehm's estimate of US34¢. He called the results "solid," praising the company for better -than-expected cost savings from recent streamlining of its research operations. The shares are currently trading at $10.15. Mr. Miehm has a target of $13 on the shares, to which he gives an "Outperform" rating. He also questioned the logic behind a possible Biovail plan to create a sales force, a move that was unsuccessfully attempted by the company several years ago. Biovail expects to make the decision within the next few months. John Greenwood  ...

Source: money.canoe.ca --- 29 days ago
TORONTO - Biovail Corp.'s (TSX:BVF) management-backed nominees for the company's board of directors were declared elected Friday at a reconvened annual meeting, after founder Eugene Melynk withdrew his dissident slate. ...

Source: www.theglobeandmail.com --- 24 days ago
Drug maker's revenue also declined in the second quarter ...

Source: www.reportonbusiness.com --- 29 days ago
Founder Eugene Melnyk votes against existing management team after dropping his own slate of directors ...

Source: www.businesswire.com --- 16 days ago
TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced the appointment of Peggy Mulligan, FCA as Chief Financial Officer, effective September 3, 2008. Mrs. ...

Source: www.businesswire.com --- 31 days ago
TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE, TSX: BVF) announced today that its Board of Directors has extended the proxy deposit deadline for the Corporation ...

Source: www.businesswire.com --- 17 days ago
TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced the appointment of Dr. Neil M. Sussman as Vice-President, Neurologic and Psychiatric Development of Biovail ...

Source: www.moreover.com --- 24 days ago
SmartBrief Aug 13 2008 12:39PM GMT ...

Source: seekingalpha.com --- 23 days ago
FP Trading Desk submits: RBC Capital Markets analyst Doug Miehm offered qualified support for drug maker Biovail Corp.'s (BVF) much talked about strategic shift into central nervous system drugs, praising management in a note this morning for doing "a good job" of explaining the new focus. However, in a note to clients Mr. Miehm went on to say he believes the company faces significant risk in implementation. Complete Story » ...